Mat Legut, OverT Bio CEO

Ex­clu­sive: New York biotech de­buts with $16M to find new ways to make sol­id can­cer cell ther­a­pies

A new biotech is com­ing out of stealth with $16 mil­lion to de­vel­op cell ther­a­pies for sol­id can­cers — an area where sci­en­tists have had lim­it­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.